Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes. RESEARCH DESIGN AND METHODS: This study includes 193,099 patients in the Kaiser Permanente Northern California diabetes registry who were ≥40 years of age between 1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes medication (defined as two or more prescriptions within 6 months) was treated as a time-dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart failure, household income, renal function, other bladder conditions, and smoking. RESULTS: The group treated with pioglitazone comprised 30,173 patients. There were 90 cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among nonpioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction P = 0.8). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [1.03–2.0]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. CONCLUSIONS: In this cohort of patients with diabetes, short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than 2 years was weakly associated with increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, some data suggest an association between the use of pioglitazone and an increased risk of bladder cancer (191).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Some research suggests that metformin use is associated with a reduced risk for various cancers (23,24); others have suggested that insulin use might increase the risk of cancer (24,25).”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Cited by
Items 201–300 of 711
A Review on Thiazolidinediones and Bladder Cancer in Human Studies
Tseng, C. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.877645 · Cited by 43
Hinnen, D. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.4.175 · Cited by 42
Toppings, N. B., McMillan, J. M., Au, P. Y. B., Suchowersky, O., & Donovan, L. (2018) · Case Reports in Endocrinology · doi:10.1155/2018/9412676 · Cited by 42
Mansure, J. J., Nassim, R., Chevalier, S., Szymanski, K. M., Rocha, J., Aldousari, S. A., & Kassouf, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055997 · Cited by 42
Lin, H., Hsu, Y.-H., Kachingwe, B. H., Hsu, C., Uang, Y., & Wang, L.-H. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12151 · Cited by 42
Ikuma, Y., Hochigai, H., Kimura, H., Nunami, N., Kobayashi, T., Uchiyama, K., Furuta, Y., Sakai, M., Horiguchi, M., Masui, Y., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.07.046 · Cited by 41
Mechanisms of current therapies for diabetes mellitus type 2
Thulé, P. M. (2012) · Advances in Physiology Education · doi:10.1152/advan.00094.2012 · Cited by 40
Management and Treatment of Diabetes Mellitus
Imam, K. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_26 · Cited by 40
Management of Nonalcoholic Steatohepatitis
Mahady, S. E., & George, J. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.003 · Cited by 40
Quan, Q., Li, X., Feng, J., Hou, J., Li, M., & Zhang, B. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11424 · Cited by 40
Pioglitazone in Clinical Practice: Where Are We Now?
Govindan, J., & Evans, M. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0001-z · Cited by 40
Yan, B., Li, X., Peng, M., Zuo, Y., Wang, Y., Liu, P., Ren, W., & Jin, X. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00997-z · Cited by 39
Chauvin, S. (2025) · Biomolecules · doi:10.3390/biom15070923 · Cited by 39
Karyekar, C. S., Ravichandran, Allen, Fleming, & Frederich, R. C. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s41246 · Cited by 39
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 39
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit
Ryder, R. E. J. (2014) · Diabetic Medicine · doi:10.1111/dme.12627 · Cited by 39
Tseng, C. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2011.10.003 · Cited by 39
DeFronzo, R. A., Mehta, R. J., & Schnure, J. J. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1062 · Cited by 39
Magliano, D. J., Davis, W. A., Shaw, J. E., Bruce, D. G., & Davis, T. M. E. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0053 · Cited by 39
Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus
Blonde, L., Juan, Z. T. S., & Bolton, P. (2014) · Endocrine Practice · doi:10.4158/ep14259.ra · Cited by 39
Ripamonti, E., Azoulay, L., Abrahamowicz, M., Platt, R. W., & Suissa, S. (2018) · Diabetic Medicine · doi:10.1111/dme.13854 · Cited by 39
The 2012 SEMDSA Guideline for the Management of type 2 Diabetes
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872277 · Cited by 39
Lin, S.-J., Zhang, Y., Liu, N.-C., Yang, D., Li, G., & Chang, C. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1422 · Cited by 38
Cancer with Diabetes: Prevalence, Metabolic Control, and Survival in an Academic Oncology Practice
Karlin, N. J., Dueck, A. C., & Cook, C. B. (2012) · Endocrine Practice · doi:10.4158/ep12128.or · Cited by 38
Detection Bias and Overestimation of Bladder Cancer Risk in Type 2 Diabetes
Colmers-Gray, I. N., Majumdar, S. R., Yasui, Y., Bowker, S. L., Marra, C. A., & Johnson, J. A. (2013) · Diabetes Care · doi:10.2337/dc13-0045 · Cited by 38
Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group (2013) · Diabetes Care · doi:10.2337/dc11-2197 · Cited by 37
Mehtälä, J., Khanfir, H., Bennett, D., Ye, Y., Korhonen, P. A., & Hoti, F. J. (2018) · Diabetology International · doi:10.1007/s13340-018-0360-4 · Cited by 37
Challenges in drug discovery for thiazolidinedione substitute
Ye, J. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.06.011 · Cited by 37
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 37
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
Han, E., Jang, S., Kim, G., Lee, Y., Choe, E. Y., Nam, C. M., & Kang, E. S. (2016) · Medicine · doi:10.1097/md.0000000000002786 · Cited by 37
Deciphering the Roles of Thiazolidinediones and PPAR γ in Bladder Cancer
Chiu, M., McBeth, L., Sindhwani, P., & Hinds, T. D. (2017) · PPAR Research · doi:10.1155/2017/4810672 · Cited by 37
Davidson, M. B., & Pan, D. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.002 · Cited by 37
Carta, A. R., & Simuni, T. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.963195 · Cited by 36
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13824 · Cited by 36
Singh, S. S. B., & Patil, K. N. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14038 · Cited by 36
The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
Song, S. O., Kim, K. J., Lee, B.-W., Kang, E. S., Cha, B. S., & Lee, H. C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.371 · Cited by 35
Diabetes and sex: from pathophysiology to personalized medicine
Abbate, R., Mannucci, E., Cioni, G., Fatini, C., & Marcucci, R. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0804-y · Cited by 35
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
Fujimoto, K., Hamamoto, Y., Honjo, S., Kawasaki, Y., Mori, K., Tatsuoka, H., Matsuoka, A., Wada, Y., Ikeda, H., Fujikawa, J., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.013 · Cited by 35
Adiponectin Signaling and Metabolic Syndrome
Fu, Y. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00009-0 · Cited by 35
Jin, S.-M., Song, S. O., Jung, C. H., Chang, J.-S., Suh, S., Kang, S. M., Jung, I., Park, C.-Y., Kim, J. H., Cho, J. H., et al. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.2.238 · Cited by 34
Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes
Tseng, C. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.851865 · Cited by 34
Diabetes Management in the Kidney Patient
Garg, R., & Williams, M. E. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.11.001 · Cited by 34
Update on Safety Issues Related to Antihyperglycemic Therapy
Carpio, G., & Fonseca, V. A. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.92 · Cited by 34
Pioglitazone use and the risk of bladder cancer
Kuo, H., Tiao, M., Ho, S., & Yang, C. (2014) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2013.09.011 · Cited by 33
Management of fatty liver disease with the metabolic syndrome
Machado, M. V., & Cortez‐Pinto, H. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.903798 · Cited by 33
Inhibition of E-cadherin expression by lnc-RNA H19 to facilitate bladder cancer metastasis
Zhu, Z., Xu, L., Wan, Y., Zhou, J., Fu, D., Chao, H., Bao, K., & Zeng, T. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170998 · Cited by 33
Natalicchio, A., Marrano, N., Montagnani, M., Gallo, M., Faggiano, A., Zatelli, M., Argentiero, A., Re, M. D., D’Oronzo, S., Fogli, S., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02417-z · Cited by 33
Safety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
Yoon, K., Steinberg, H. O., Teng, R., Golm, G. T., Lee, M. M.-S., O’Neill, E. A., Kaufman, K. D., & Goldstein, B. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01594.x · Cited by 33
Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan
Ohkura, T. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.136 · Cited by 33
Diabetes and cancer: A 2013 synopsis
Buysschaert, M., & Sadikot, S. S. (2013) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.08.001 · Cited by 33
Terrasi, M., Bazan, V., Caruso, S., Insalaco, L., Amodeo, V., Fanale, D., Corsini, L. R., Contaldo, C., Mercanti, A., Fiorio, E., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24295 · Cited by 33
Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus.
Onge, E. S., Miller, S. A., & Clements, E. A. (2012) · PubMed · Cited by 33
The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease
Bril, F., Lomonaco, R., & Cusi, K. (2012) · Clinical Lipidology · doi:10.2217/clp.12.47 · Cited by 32
PPARγ in head and neck cancer prevention
Burotto, M., & Szabo, E. M. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2013.12.020 · Cited by 32
Balaji, V., Seshiah, V., Ashtalakshmi, G., Ramanan, S., & Janarthinakani, M. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131223 · Cited by 32
Emad, N. A., Sultana, Y., Aqil, M., Saleh, A., Kamaly, O. M. A., & Nasr, F. A. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103778 · Cited by 31
Pioglitazone: Indian perspective
Shukla, R., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85581 · Cited by 31
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γAgonist against MPTP
Swanson, C. R., Du, E. Y., Johnson, D. A., Johnson, J. A., & Emborg, M. E. (2013) · PPAR Research · doi:10.1155/2013/582809 · Cited by 31
Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra
Whitehead, J. P. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.04.017 · Cited by 31
Suzuki, S., Mori, Y., Nagano, A., Naiki‐Ito, A., Kato, H., Nagayasu, Y., Kobayashi, M., Kuno, T., & Takahashi, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122071 · Cited by 31
Adil, M., Khan, R. A., Ghosh, P., Venkata, S. K., Kandhare, A. D., & Sharma, M. (2017) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2017.08.002 · Cited by 31
Cheng, Q., Li, Y. W., Yang, C., Zhong, Y., & Li, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00949 · Cited by 31
Advances in the management of diabetes: therapies for type 2 diabetes
Tsoutsouki, J., Wunna, W., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137404 · Cited by 31
Vascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 31
Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke
Kikuchi, K., Uchikado, H., Morioka, M., Murai, Y., & Tanaka, E. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13067739 · Cited by 31
Faillie, J., Petit, P., Montastruc, J., & Hillaire‐Buys, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0086-y · Cited by 30
Lee, M., Hsiao, P., Yang, Y., Lin, K., & Shin, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085479 · Cited by 30
Alba, M., Åhrén, B., Inzucchi, S. E., Guan, Y., Mallick, M., Xu, L., O’Neill, E. A., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12145 · Cited by 30
Harman, E., Erten, Ç., Küçükzeybek, Y., Dırıcan, A., Er, H., & Oktay, T. M. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.10.5143 · Cited by 30
Interpreting Adverse Signals in Diabetes Drug Development Programs
Bailey, C. J. (2013) · Diabetes Care · doi:10.2337/dc13-0182 · Cited by 30
Kao, C., Sun, L. M., Chen, P., Lin, M.-C., Liang, J., Muo, C.-H., Chang, S.-N., & Sung, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds472 · Cited by 30
Pοlyzos, S. A., Bugianesi, E., Kountouras, J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.001 · Cited by 30
PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma
Kimura, O. S., Kondo, Y., & Shimosegawa, T. (2012) · PPAR Research · doi:10.1155/2012/574180 · Cited by 30
Management of Blood Glucose with Noninsulin Therapies in Type 2 Diabetes.
George, C. M., Brujin, L. L., Will, K. J., & Howard-Thompson, A. (2015) · PubMed · Cited by 30
Vaccaro, O., Masulli, M., Bonora, E., Prato, S. D., Nicolucci, A., Rivellese, A. A., Riccardi, G., & on behalf of the TOSCA.IT Study Group (2012) · Diabetes Care · doi:10.2337/dc12-0954 · Cited by 28
Drug–subphenotype interactions for cancer in type 2 diabetes mellitus
Yang, X., Lee, H. M., & Chan, J. C. N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.37 · Cited by 28
Lewis, J. D., Habel, L., Quesenberry, C., Mamtani, R., Peng, T., Bilker, W. B., Hedderson, M., Nessel, L., Vaughn, D. J., Strom, B. L., et al. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3619 · Cited by 27
Self-citationThe Importance of Rhodanine Scaffold in Medicinal Chemistry: A Comprehensive Overview
Mermer, A. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666201217144954 · Cited by 27
Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors
Gandomani, H. S., Tarazoj, A. A., Siri, F. H., Rozveh, A. K., Hosseini, S., Borujeni, N. N., Mohammadian-Hafshejani, A., & Salehiniya, H. (2017) · Biomedical Research and Therapy · doi:10.15419/bmrat.v4i9.371 · Cited by 27
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
Goyard, D., Baron, M., Skourti, P. V., Chajistamatiou, A. S., Docsa, T., Gergely, P., Chrysina, E. D., Praly, J., & Vidal, S. (2012) · Carbohydrate Research · doi:10.1016/j.carres.2012.09.020 · Cited by 26
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile
Obermoser, V., Urban, M. E., Murgueitio, M. S., Wolber, G., Kintscher, U., & Gust, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.027 · Cited by 26
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
Papanagnou, P., Stivarou, T., & Tsironi, M. (2016) · Pharmaceuticals · doi:10.3390/ph9020024 · Cited by 26
The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease
Alkhouri, N., Feldstein, A. E., Groszmann, R. J., Iwakiri, Y., & Taddei, T. H. (2012) · Hepatology · doi:10.1002/hep.24767 · Cited by 25
Yang, J., Vallarino, C. R., Bron, M., Pérez, A., Liang, H., Joseph, G. L., & Yu, S. S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.941054 · Cited by 25
Idealized PPAR-Based Therapies: Lessons from Bench and Bedside
Amato, A. A., & Neves, F. D. A. R. (2012) · PPAR Research · doi:10.1155/2012/978687 · Cited by 25
Nonalcoholic fatty liver disease and bariatric surgery in adolescents
Holterman, A., Gurria, J. P., Tanpure, S., & DiSomma, N. M. (2013) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2013.10.016 · Cited by 24
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Monnier, L., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.003 · Cited by 24
Zhou, L., Zhong, Y., Xue, M., Kuang, D., Cao, X., Zhao, Z., Li, H., Xu, Y. F., & Wang, R. (2014) · Chinese Chemical Letters · doi:10.1016/j.cclet.2014.10.008 · Cited by 24
Nicholls, S. J., & Uno, K. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441477 · Cited by 24
Ansaloni, M., & Smith, A. (2018) · Gouvernement et action publique · doi:10.3917/gap.181.0033 · Cited by 24
Improving diabetes management with electronic medical records
Varroud-Vial, M. (2011) · Diabetes & Metabolism · doi:10.1016/s1262-3636(11)70965-x · Cited by 24
Review of refractory ceramic fiber (RCF) toxicity, epidemiology and occupational exposure
Maxim, L. D., & Utell, M. J. (2018) · Inhalation Toxicology · doi:10.1080/08958378.2018.1448019 · Cited by 24
Chen, K.-C., Yin, W. H., Wu, C., Chan, S. H., Wu, Y., Wang, K. Y., Chang, K.-C., Hwang, J., Voon, W., Hsieh, C., et al. (2018) · Europe PMC (PubMed Central) · doi:10.6515/acs.201805_34(3).20180207b · Cited by 23
Hickson, R. P., Cole, A. L., & Dusetzina, S. B. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.1.072 · Cited by 23
Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
Gupta, S., Gupta, K., Ravi, R., Mehta, V., Banerjee, S., Joshi, S., & Saboo, B. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163187 · Cited by 23
Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus
Goldman, J. D. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.44s · Cited by 23
Personalizing guidelines for diabetes management: twilight or dawn of the expert?
Paschou, S. Α., & Leslie, R. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-161 · Cited by 23
Metformin therapy and prostate cancer risk: a meta-analysis of observational studies.
Wu, G., Zhang, X., Luo, Z., Yan, J., Pan, S., Ying, X., Pan, J., & Zhang, G.-F. (2015) · Europe PMC (PubMed Central) · Cited by 23
Metadata
- Authors
- Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L.
- Affiliations
- University of Pennsylvania (US)
- Kaiser Permanente (US)
- Corresponding author
- Lewis, James D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 916-922
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3064051
- OpenAlex
- W2121264929
- Cited by
- 625
- References
- 24
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 19 · 2021: 18 · 2020: 25 · 2019: 21 · 2018: 29 · 2017: 35 · 2016: 55 · 2015: 58 · 2014: 79 · 2013: 90 · 2012: 119
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug safety, cancer risk, treatment duration, thiazolidinediones, antidiabetic drugs, early-stage cancer detection
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.